Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand 
HSBC Expands UAE Presence With New Asset Management Business and Onshore Funds 
Starlink Internet Remains Active in Iran Despite Nationwide Blackout 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
NYC Nurses Strike Shuts Down 10 Private Hospitals as 15,000 Demand Safer Staffing and Benefits 
Rio Tinto–Glencore Talks Spark Pressure on BHP as Copper Fuels Mining Mega Deals 
AbbVie Commits $100 Billion to U.S. Investment in Drug Pricing Deal With Trump Administration 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
Trump Pushes Tech Giants to Absorb AI Data Center Power Costs, Citing Microsoft Changes 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable” 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
BOSTON, March 28, 2017 -- Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that management will present at the following investor conferences in April:
| 1st Annual H.C. Wainwright & Company NASH Investor Conference | |
| Location: St. Regis New York in New York City (Versailles Room) | |
| Presentation date / time: Monday, April 3, 2017, at 11:00 a.m. ET | |
| Presenter: Paresh N. Soni, MD, PhD, Chief Medical Officer | |
| 16th Annual Needham Healthcare Conference | |
| Location: Westin Grand Central Hotel in New York City | |
| Presentation date / time: Tuesday, April 4, 2017, at 3:00 p.m. ET | |
| Presenter: Ron Cooper, President and Chief Executive Officer | |
A live audio webcast of the Needham conference presentation will be accessible from the Investors page of Albireo’s website, ir.albireopharma.com. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will be available for replay on the Events & Presentations section of the Investors page of Albireo’s website for at least two weeks following the event.
About Albireo
Albireo is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo’s clinical pipeline includes two Phase 2 product candidates and one Phase 3 product candidate. Albireo was spun out from AstraZeneca in 2008.
Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary, Albireo AB, is located in Gothenburg, Sweden. For more information on Albireo, please visit www.albireopharma.com.
Source: Albireo Pharma, Inc.
Investor Contact: Hans Vitzthum LifeSci Advisors, LLC. 212-915-2568 Media Contact: Heather Anderson 6 Degrees 980-938-0260 [email protected]
